Related Experiment Videos
Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets
Dag Nyholm1, Håkan Askmark, Cecilia Gomes-Trolin
1Department of Neuroscience, Neurology, Uppsala University, Sweden. dag.nyholm@neurologi.uu.se
Clinical Neuropharmacology
|June 5, 2003
Summary
Continuous intestinal infusion of carbidopa/levodopa gel significantly improved motor control in advanced Parkinson's disease (PD) patients. This method reduced motor fluctuations, offering better symptom management than oral sustained-release formulations.
Area of Science:
- Neurology
- Pharmacology
- Gastroenterology
Background:
- Advanced Parkinson's disease (PD) often involves motor fluctuations despite oral therapies.
- Continuous duodenal infusion of carbidopa/levodopa is a potential strategy to manage these symptoms.
Purpose of the Study:
- To compare the pharmacokinetics of levodopa and 3-O-methyldopa.
- To evaluate motor performance with continuous intestinal levodopa infusion versus oral sustained-release carbidopa/levodopa in advanced PD patients.
Main Methods:
- A randomized crossover trial involving 12 patients with advanced PD.
- Patients received carbidopa/levodopa via oral sustained-release tablets and nasoduodenal continuous infusion for 3 weeks each.
- Plasma levodopa concentrations and motor performance were assessed regularly.
Main Results:
- Continuous infusion resulted in significantly lower plasma levodopa variability (14%) compared to oral therapy (34%).
- Patients experienced increased ON time and decreased OFF time and dyskinesia with continuous infusion.
- Motor performance showed marked improvement during intestinal infusion.
Conclusions:
- Continuous intraduodenal delivery of a new carbidopa/levodopa gel formulation provides superior control of motor fluctuations in advanced PD.
- This delivery method offers a significant advancement in managing motor symptoms for late-stage Parkinson's disease patients.